Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Levothyroxine Bioequivalence Studies Need Thyroid-Free Baseline – Abbott

Executive Summary

FDA should require generic companies to conduct levothyroxine bioequivalence studies in athyreotic patients as a condition of ANDA approval, Abbott suggests in an Aug. 25 citizen petition
Advertisement

Related Content

Abbott Predicts Arthritis Therapy Humira Will Top $1 Bil. In 2005
Abbott Predicts Arthritis Therapy Humira Will Top $1 Bil. In 2005
Levothyroxine Review Standards Should Be Same For ANDAs, Brands – Petition
Levothyroxine Review Standards Should Be Same For ANDAs, Brands – Petition
Levothyroxine BE Studies In Athyreotic Patients Would Be “Unrealistic” – FDA
Levothyroxine BE Studies In Athyreotic Patients Would Be “Unrealistic” – FDA
Synthroid Sales Expected To Grow 12% For Year Following NDA Approval
Advertisement
UsernamePublicRestriction

Register

PS042428

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel